CMSNational Coverage Determination (NCD)

Anti-Inhibitor Coagulant Complex (AICC) Form

Chat with GenHealth to automate any policy or prior auth task.


Anti-Inhibitor Coagulant Complex

Notes: AICC has Medicare coverage under specified conditions for patients with hemophilia A.

Indications

(84981) Is the patient diagnosed with hemophilia A with inhibitor antibodies to factor VIII? 
(84982) Is the AICC being used to treat a major bleeding episode? 
(84983) Has the patient failed to respond to other, less expensive therapies? 

Effective Date

01/01/2066

Last Reviewed

NA

Original Document

  Reference


Related policies from health plans

Anti-Inhibitor Coagulant Complex (AICC)
Adefovir Dipivoxil (Hepsera) (PG081)
Adefovir Dipivoxil (Hepsera) (PG081)
Apretude (cabotegravir extended-release injectable suspension) (PG158)
Apretude (cabotegravir extended-release injectable suspension) (PG158)
Antidiabetic Agents - Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & SGLT2 Antidiabetic Combinations (PG154)
Antidiabetic Agents - Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & SGLT2 Antidiabetic Combinations (PG154)
Allergen Immunotherapy
Allergen Immunotherapy

Anti-inhibitor coagulant complex, AICC, is a drug used to treat hemophilia in patients with factor VIII inhibitor antibodies. AICC has been shown to be safe and effective and has Medicare coverage when furnished to patients with hemophilia A and inhibitor antibodies to factor VIII who have major bleeding episodes and who fail to respond to other, less expensive therapies.

Book a walkthrough

Walk through this policy with us

Review how this policy can be converted into cited criteria, prior authorization checks, and operational automation.